0000000000648367

AUTHOR

M. Rivero

showing 9 related works from this author

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

2020

Abstract Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed …

Male0301 basic medicinePsychological interventionHuman immunodeficiency virus (HIV)MedizinContinuum of care; Europe; HIV infection; Key population; Sex; Anti-Retroviral Agents; Continuity of Patient Care; European Union; HIV; Humans; Male; HIV InfectionsHIV InfectionsContinuum of care; Europe; HIV infection; Key population; Sexmedicine.disease_causekey population0302 clinical medicineContinuum of careHIV Infection030212 general & internal medicineMen having sex with menContinuum of caremedia_commoneducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTransmission (medicine)Continuity of Patient CareEuropeInfectious DiseasesAcademicSubjects/MED00290Anti-Retroviral AgentsHIV infection continuum of care sex key population EuropeSexMicrobiology (medical)PopulationSocio-culturale03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationPandemicsHIV infection ; continuum of care ; sex ; key population ; Europebusiness.industrySARS-CoV-2COVID-19HIVmedicine.diseaseHIV infectioncontinuum of care030112 virologyMajor Articles and CommentariesKey populationAnti-Retroviral Agentbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemography
researchProduct

P275 Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Span…

2018

medicine.medical_specialtyCrohn's diseasemedicine.diagnostic_testbusiness.industryColorectal cancermedicine.medical_treatmentGastroenterologyColonoscopyGeneral MedicineJaundiceLiver transplantationmedicine.diseaseUlcerative colitisInflammatory bowel diseaseTransplantation03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineMedicine030211 gastroenterology & hepatologymedicine.symptombusinessJournal of Crohn's and Colitis
researchProduct

Search for $B^0_s-\overline{B^0_s}$ oscillations and a measurement of $B^0_d-\overline{B^0_d}$ oscillations using events with an inclusively reconstr…

2003

Neutral B meson oscillations in the B-s(0) - , and B-d(0) - systems were studied using a sample of about 4.0 million hadronic Z decays recorded by the DELPHI detector between 1992 and 2000. Events with a high transverse momentum lepton were removed and a sample of 770 k events with an inclusively reconstructed vertex was selected. The mass difference between the two physical states in the B-d(0) - system was measured to be: Deltam(d) = (0.531 +/- 0.025(stat.) +/- 0.007(syst.))ps(-1). The following limit on the width difference of these states was also obtained: DeltaGamma(Bd)/Gamma(Bd) oscillations was found, a limit on the mass difference of the two physical states was given:, Deltam(s) > …

PhysicsParticle physicsPhysics and Astronomy (miscellaneous)010308 nuclear & particles physicsPhysicsElectron–positron annihilationHadron01 natural sciencesVertex (geometry)Nuclear physics0103 physical sciencesTransverse momentumHigh Energy Physics::ExperimentB meson010306 general physicsEngineering (miscellaneous)LeptonThe European Physical Journal C
researchProduct

P630 Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

2021

Abstract Background Previous studies comparing inflammatory bowel disease(IBD) features between migrant and native patients have shown clinical phenotype differences. To date, no study has focused on IBD immigrants(MP) in Spain. The aim of this study was to explore the features of MP in Spain and to compare age of disease onset, IBD phenotype and therapeutic requirements with native-born IBD patients(NP). Methods This was an observational, multicentric and case-control study of the nationwide ENEIDA registry. We selected all IBD patients who were born outside of Spain and compared with a control cohort of NP. All included patients were diagnosed with IBD before 2015. Results A total of 13,5…

medicine.medical_specialtybusiness.industrymedia_common.quotation_subjectInternal medicineImmigrationGastroenterologymedicineGeneral Medicinemedicine.diseasebusinessInflammatory bowel diseasemedia_commonJournal of Crohn's and Colitis
researchProduct

Masses, lifetimes and production rates of Ξ− and Ξ¯+ at LEP 1

2006

Measurements of the Xi(-) and (Xi) over bar (+) masses, mass differences, lifetimes and lifetime differences are presented. The (Xi) over bar (+) sample used is much larger than those used previously for such measurements. In addition, the S production rates in Z -> b (b) over bar and Z -> q (q) over bar events are compared and the position xi* of the maximum of the distribution in Z -> q (q) over bar events is measured.

PhysicsNuclear physicsNuclear and High Energy Physics010308 nuclear & particles physicsElectron–positron annihilation0103 physical sciencesProduction (computer science)010306 general physics01 natural sciencesBar (unit)Xi baryonPhysics Letters B
researchProduct

Measurement of the Λb0 decay form factor

2004

The form factor of Λb0 baryons is estimated using 3.46×106 hadronic Z decays collected by the DELPHI experiment between 1992 and 1995. Charmed Λc+ baryons fully reconstructed in the pK-π+, pK S0, and Λπ+π+π - modes, are associated to a lepton with opposite charge in order to select Λb0→Λc+l-ν̄l decays. From a combined likelihood and event rate fit to the distribution of the Isgur-Wise variable w, and using the Heavy Quark Effective Theory (HQET), the slope of the b-baryon form factor is measured to be ρ̂2=2.03±0.46(stat) -1.00+0.72(syst). The exclusive semileptonic branching fraction Br(Λb0→Λc+l-ν̄l) can be derived from ρ̂2 and is found to be (5.0-0.8+1.1(stat)-1.2+1.6(syst))%. Limits on ot…

Semileptonic decayPhysicsParticle physicsNuclear and High Energy Physics010308 nuclear & particles physicsBranching fractionElectron–positron annihilationHadronLambdaLambda baryon01 natural sciencesNuclear physicsBaryon0103 physical sciences010306 general physicsLepton
researchProduct

A measurement of the branching fractions of the b quark into charged and neutral b hadrons

2003

The production fractions of charged and neutral b-hadrons in b-quark events from Z0 decays have been measured with the DELPHI detector at LEP. An algorithm has been developed, based on a neural network, to estimate the charge of the weakly-decaying b-hadron by distinguishing its decay products from particles produced at the primary vertex. From the data taken in the years 1994 and 1995, the fraction of bbar-quarks fragmenting into positively charged weakly-decaying b-hadrons has been measured to be: f^+ = (42.09 +/- 0.82 (stat.) +/- 0.89 (syst.))%. Subtracting the rates for charged Xibar_b^+ and Omegabar_b^+ baryons gives the production fraction of B^+ mesons: f_Bu = (40.99 +/- 0.82 (stat.)…

QuarkParticle physicsNuclear and High Energy PhysicsMesonElectron–positron annihilationHadronNuclear TheoryFOS: Physical sciencesLIFETIMEBranching (polymer chemistry)01 natural sciencesBottom quarkOmegaHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsNuclear ExperimentZ-DECAYSDELPHIPhysicsBARYONS010308 nuclear & particles physicsPhysicsHigh Energy Physics::PhenomenologyLEPMESONSLARGE ELECTRON POSITRON COLLIDERBaryonPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIZ-DECAYS; LIFETIME; BARYONS; MESONS; LEPPARTICLE PHYSICSHigh Energy Physics::ExperimentParticle Physics - Experiment
researchProduct

Search for neutral MSSM Higgs bosons at LEP

2006

The four LEP collaborations, ALEPH, DELPHI, L3 and OPAL, have searched for the neutral Higgs bosons which are predicted by the Minimal Supersymmetric Standard Model (MSSM). The data of the four collaborations are statistically combined and examined for their consistency with the background hypothesis and with a possible Higgs boson signal. The combined LEP data show no significant excess of events which would indicate the production of Higgs bosons. The search results are used to set upper bounds on the cross-sections of various Higgs-like event topologies. The results are interpreted within the MSSM in a number of "benchmark" models, including CP-conserving and CP-violating scenarios. Thes…

AlephPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; ALEPH; DELPHI; L3; OPALPhysics and Astronomy (miscellaneous)Parameter space01 natural sciencesOPAL DETECTORHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Event (probability theory)BosonPhysicsEXPLICIT CP VIOLATIONROOT-S=189 GEVOPALFLAVOR INDEPENDENT SEARCHParticle physics - ExperimentPhysicsSettore FIS/01 - Fisica SperimentaleHiggs particle. search forSUPERGAUGE TRANSFORMATIONSALEPHLARGE ELECTRON POSITRON COLLIDERALEPH DELPHI L3 OPALSUPERSYMMETRIC STANDARD MODELROOT-SL3Higgs bosonPARTICLE PHYSICSParticle physicselectron positron. colliding beamselectron positron. annihilationFOS: Physical sciencessupersymmetric standard model;; explicit cp violation;; electric-dipole moment;; e(+)e(-) collisions;; root-s=189 gev;; opal detector;; root-s;; z(0) decays;; supergauge transformations;; radiative-correctionsHiggs particle. electroproductionddc:500.2-SUPERSYMMETRIC STANDARD MODEL; EXPLICIT CP VIOLATION; FLAVOR INDEPENDENT SEARCH; ELECTRIC-DIPOLE MOMENT; E(+)E(-) COLLISIONS; ROOT-S; ROOT-S=189 GEV; OPAL DETECTOR; Z(0) DECAYS; SUPERGAUGE TRANSFORMATIONSHiggs particleLEP colliderNext-to-Minimal Supersymmetric Standard ModelELECTRIC-DIPOLE MOMENTE(+)E(-) COLLISIONSConsistency (statistics)0103 physical sciencesddc:530High Energy Physics010306 general physicsEngineering (miscellaneous)DELPHIelectron positron010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyHiggs BosonLEPHIGGSHiggs boson standard modelZ(0) DECAYSExperimental High Energy PhysicsHigh Energy Physics::ExperimentHiggs Boson; LEP colliderMSSMMinimal Supersymmetric Standard ModelHiggs
researchProduct